Pharmaceutical News

RSS

SSRIs may minimize risk of Sudden Unexpected Death in Epilepsy

A groundbreaking study published in Elsevier's Epilepsy & Behavior provides evidence in mouse model that drugs known as Selective Serotonin Reuptake Inhibitors (SSRIs; one category of antidepressants) may reduce the risk of Sudden Unexpected Death in Epilepsy (SUDEP).

9 Feb 2012

Mylan's generic Doryx ANDA receives final FDA approval

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg. This product is the generic version of Mayne Pharma's Doryx, which is a tetracycline-class antimicrobial.

9 Feb 2012

FDA panel votes against Amgen’s Xgeva in prostate cancer

An FDA panel of oncologists has voted against a new use for Amgen's Xgeva in prostate cancer on Wednesday, saying the drug's ability to slow the spread of the disease did not translate into meaningful benefits for patients. Xgeva is already approved to prevent fractures in cancerous bones, and for osteoporosis, in a different formulation called Prolia.

9 Feb 2012

Acid reducing drugs could raise risk of C. diff diarrhea

U.S. health regulators, the Food and Drugs Administration (FDA), have announced that ulcer drugs such as AstraZeneca Plc's blockbuster Nexium could increase the risk of Clostridium difficile-associated diarrhea (CDAD).

9 Feb 2012

Combination of anti-obesity drugs and lifestyle advice effective in reducing weight, BMI

A study led by the University of Leicester has found that anti-obesity drugs coupled with lifestyle advice are effective in reducing weight and BMI.

9 Feb 2012

New iHeal project aims to detect drug cravings and prevent medication use

Imagine a device combining sensors to measure physiological changes. Then imagine a smartphone with software applications designed to respond to your bodily changes in an attempt to change your behavior. That is the vision behind "iHeal," currently being developed- by Edward Boyer from the University of Massachusetts Medical School in the US, and his colleagues.

9 Feb 2012

Antidepressants make patients feel less satisfied after THR

Patients taking antidepressants up to three years prior to undergoing a total hip replacement (THR) were more likely to report greater pain before and after surgery and less satisfaction with their procedure, according to new research presented today at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).

9 Feb 2012

Stimulants do not increase risk of cardiovascular events in youth with ADHD

Attention-deficit/hyperactivity disorder (ADHD) affects 5-9% of youth and is frequently treated with stimulant medications, such as methylphenidate and amphetamine products. A recent safety communication from the US Food and Drug Administration advised that all patients undergoing ADHD treatment be monitored for changes in heart rate or blood pressure.

9 Feb 2012

Fasting and chemotherapy drugs more effectively treat cancers

Man may not live by bread alone, but cancer in animals appears less resilient, according to a study that found chemotherapy drugs work better when combined with cycles of short, severe fasting.

9 Feb 2012

Apotex makes payment to Sanofi, Bristol-Myers Squibb to satisfy damages in Plavix patent litigation

Sanofi and Bristol-Myers Squibb Company announced today that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to satisfy the damages ruling of the Plavix (clopidogrel bisulfate) patent infringement case against Apotex.

9 Feb 2012

Scientists study a botanical formula that kills aggressive prostate cancer tumors

Scientists at Indiana University, Methodist Research Institute study a botanical formula that kills aggressive prostate cancer tumors. Their findings, based on experiments in mice using a human prostate cancer tumor model, appear online in The International Journal of Oncology.

9 Feb 2012

$Bisphosphonates may raise risk of atypical femur fracture$

Bisphosphonates may raise risk of atypical femur fracture

There is growing evidence that supports an association between atypical fractures of the femur- a rare break of the thigh bone, typically without trauma - and the use of bisphosphonates, drugs proven to enhance bone density and reduce fracture incidence caused by osteoporosis.

9 Feb 2012

Watson settles ORTHO TRI-CYCLEN LO patent litigation with Janssen

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has reached a settlement with Janssen Pharmaceuticals, Inc. on outstanding patent litigation related to Watson's generic version of Janssen's ORTHO TRI-CYCLEN LO (norgestimate/ethinyl estradiol) tablets.

8 Feb 2012

RV5 vaccination does not increase risk of intussusception in infants

Although some data have suggested a possible increased risk of intussusception (when a portion of the small or large intestine slides forward into itself, like a telescope) after administration of the pentavalent rotavirus vaccine in infants, an analysis that included almost 800,000 doses administered to U.S. infants found no increased risk of this condition following vaccination, according to a study in the February 8 issue of JAMA.

8 Feb 2012

Guardian blog interviews researcher regarding artemisinin synthesis discovery

In this post in the Guardian's "The Observer," Mark Honigsbaum, a research associate at the University of Zurich's Institute for Medical History, interviews Peter Seeberger, the director of the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany, about a recent announcement that Seeberger and colleague François Lévesque "have discovered a simple and cost-effective way of synthesizing artemisinin from the waste products of the" sweet wormwood plant from which it is extracted.

8 Feb 2012

APP to launch Meropenem, Cilastatin and Imipenem in the U.S.

APP Pharmaceuticals, Inc., a Fresenius Kabi Company, announced today that it will launch both Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP in the United States. APP will begin shipping Meropenem for Injection the week of February 13, 2012 with Imipenem and Cilastatin for Injection scheduled to ship in the next three to five weeks.

8 Feb 2012

Scientists reveal how psychostimulant drugs work to control hyperactivity

It has long been known that psychostimulant drugs have the paradoxical effect of reducing hyperactivity. [Psychostimulant drugs include methylphenidate - known by the trade names Ritalin, Concerta, and Methylin - and methamphetamine]. Since the mid-1950s, millions of children and adults have been prescribed stimulant medications to control attention deficit hyperactivity disorder.

8 Feb 2012

GSK launches Medivir's Xerclear for OTC use in Europe

Medivir AB, the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe.

8 Feb 2012

Study determines prevalence of vitamin D deficiency among post menopausal women with DRF

Wrist fractures, also called distal radius fractures (DRF), are among the most common osteoporosis-related fractures occurring on average 15 years earlier than hip fractures. As vitamin D deficiency has recently been linked with muscle weakness, increased fall risks, and bone fractures, investigators sought to determine the prevalence of vitamin D deficiency among post menopausal women with DRF.

8 Feb 2012

Tips to understand drug-related recall

With the new year came many drug recalls. In the first six weeks of 2012, there were at least 13 drug-related recalls. Some were due to bacterial contamination. Eight distinct bacterial contaminants were identified in one over-the-counter product.

8 Feb 2012